Researchers at Case Western Reserve University, University Hospitals and Houston Methodist will harness the power of artificial intelligence (AI) to more accurately predict risk of heart failure and other cardiovascular events, including estimating when an adverse event might occur, by developing an AI model that “learns” from patient scans.
BT-7480 by Bicycle Therapeutics for Solid Tumor: Likelihood of Approval
BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Solid Tumor.